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The mTORC1/4E-BP1 axis represents a critical
signaling node during ﬁbrogenesis
Hannah V. Woodcock1, Jessica D. Eley1, Delphine Guillotin1, Manuela Platé 1, Carmel B. Nanthakumar2,
Matteo Martuﬁ3, Simon Peace2, Gerard Joberty4, Daniel Poeckel4, Robert B. Good2, Adam R. Taylor2,
Nico Zinn4, Matthew Redding1, Ellen J. Forty1, Robert E. Hynds 5,6, Charles Swanton5,6, Morten Karsdal7,
Toby M. Maher8, Giovanna Bergamini4, Richard P. Marshall2, Andy D. Blanchard2, Paul F. Mercer1 &
Rachel C. Chambers 1
Myoﬁbroblasts are the key effector cells responsible for excessive extracellular matrix
deposition in multiple ﬁbrotic conditions, including idiopathic pulmonary ﬁbrosis (IPF). The
PI3K/Akt/mTOR axis has been implicated in ﬁbrosis, with pan-PI3K/mTOR inhibition cur-
rently under clinical evaluation in IPF. Here we demonstrate that rapamycin-insensitive
mTORC1 signaling via 4E-BP1 is a critical pathway for TGF-β1 stimulated collagen synthesis in
human lung ﬁbroblasts, whereas canonical PI3K/Akt signaling is not required. The impor-
tance of mTORC1 signaling was conﬁrmed by CRISPR-Cas9 gene editing in normal and IPF
ﬁbroblasts, as well as in lung cancer-associated ﬁbroblasts, dermal ﬁbroblasts and hepatic
stellate cells. The inhibitory effect of ATP-competitive mTOR inhibition extended to other
matrisome proteins implicated in the development of ﬁbrosis and human disease relevance
was demonstrated in live precision-cut IPF lung slices. Our data demonstrate that the
mTORC1/4E-BP1 axis represents a critical signaling node during ﬁbrogenesis with potential
implications for the development of novel anti-ﬁbrotic strategies.
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F ibrosis, deﬁned as the abnormal accumulation of extra-cellular matrix (ECM), is a pathological feature of manychronic inﬂammatory and metabolic diseases and is often
closely linked with organ dysfunction and, ultimately, organ
failure1,2. The importance of the stroma in inﬂuencing cancer
progression is also gaining increasing recognition1,3. Despite this
high unmet clinical need, only two anti-ﬁbrotic drugs, Pirfeni-
done/Esbriet® and Nintedanib/Ofev® have been approved to date.
Moreover, these agents slow rather than halt disease progression
in idiopathic pulmonary ﬁbrosis (IPF)4,5, the most rapidly pro-
gressive and fatal of all ﬁbrotic conditions. The underlying
etiology of IPF remains poorly understood although current
evidence suggests this condition likely arises as a result of a highly
dysregulated wound healing response following chronic epithelial
injury on the background of a combination of genetic predis-
position and environmental factors (including cigarette smoking)
and cellular senescence associated with ageing6–8. Highly syn-
thetic and α-smooth muscle actin positive myoﬁbroblasts are
regarded the key effector cells of the ﬁbrogenic response during
both normal wound healing and in the context of pathological
ﬁbrosis9, including IPF10–13. The persistence of these cells, as a
result of a failure in apoptosis, is felt to be a key event in the
initiation and progression of ﬁbrosis14. In terms of key mediators
involved in promoting excessive myoﬁbroblast differentiation and
ﬁbrogenesis, current evidence points to a key role for the pleio-
tropic cytokine, transforming growth factor-β (in particular the
TGF-β1 isoform), in multiple ﬁbrotic conditions15. TGF-β1 sig-
nals through the canonical Smad pathway and several non-
canonical pathways to inﬂuence cellular function in a cell-speciﬁc
and cell-context dependent manner. Therapeutic strategies aimed
at targeting the dysregulated TGF-β1 axis in ﬁbrosis, without
compromising its critical roles in tissue and immune homeostasis,
are being intensely pursued16.
The phosphoinositide-3-kinase (PI3K)/mechanistic target of
rapamycin (mTOR) signaling pathway plays a central role in
regulating a broad range of fundamental cellular processes,
including metabolism, cell cycle progression, proliferation,
growth, autophagy, and protein synthesis17. Activation of class 1
PI3K results in the production of membrane-localized phospha-
tidylinositol-3,4,5-trisphosphate (PIP3) and recruitment of Akt
via its pleckstrin homology domain. mTOR functions at two
distinct nodes in this signaling axis. mTOR complex 2
(mTORC2) and 3-phosphoinositide-dependent protein kinase-1
(PDK1) phosphorylate Akt at the plasma membrane to stabilize
the catalytic site of Akt for maximal activation18. Once activated,
Akt phosphorylates the TSC2 subunit of the tuberous sclerosis
complex (TSC), a key control switch for mTORC1. Phosphor-
ylation and inhibition of TSC2 lead to the accumulation of GTP-
bound RAS homologue enriched in brain (Rheb) and activation
of mTORC1 signaling via several downstream substrates,
including p70S6K and eukaryotic translation initiation factor 4E-
binding protein 1 (4E-BP1)19.
The PI3K/mTOR pathway has previously been implicated in
inﬂuencing ﬁbroblast proliferative responses and TGF-β1-induced
myoﬁbroblast differentiation and collagen production20,21. More
recently, we provided a strong scientiﬁc rationale for progressing
the potent pan-PI3 kinase/mTOR inhibitor Omipalisib
(GSK2126458) as a novel anti-ﬁbrotic agent in a proof-of-
mechanism trial in IPF (https://clinicaltrials.gov/ct2/show/
NCT01725139)22. Omipalisib displays broad target speciﬁcity
and may overcome functional redundancy between PI3K iso-
forms and compensatory feedback loops in this pathway but on-
target-toxicities associated with this class of inhibitors could be
limiting23–25.
The mechanism by which the PI3K/mTOR pathway regulates
TGF-β1-induced collagen synthesis is poorly understood. In this
study, we characterize a unique toolbox of commercially available
and proprietary pharmacological inhibitors and use these in
combination with CRISPR-Cas9 gene editing and siRNA
approaches to deconvolute the mechanism by which pan-PI3
kinase/mTOR inhibition blocks TGF-β1-induced collagen synth-
esis in primary human lung ﬁbroblasts (pHLFs). We show that
the potent ﬁbrogenic effects of TGF-β1 are mediated via the
cooperation between canonical Smad3 and rapamycin-insensitive
mTORC1/4E-BP1 signaling and that the canonical PI3K–Akt axis
is dispensable for this response. Furthermore, ATP-competitive
mTOR inhibition halts collagen synthesis in live unmanipulated
precision-cut IPF lung slices. The critical role of the mTORC1/
4E-BP1 axis in inﬂuencing collagen synthesis is further general-
izable to ﬁbrogenic cells implicated in the development of ﬁbrosis
in the liver and skin, as well as the stromal reaction in lung
cancer. Taken together, these experiments shed light on the sig-
naling pathways by which TGF-β1 exerts its potent ﬁbrogenic
effects and provide support for selectively targeting
mTORC1 signaling in IPF and potentially other ﬁbrotic
conditions.
Results
TGF-β1-induced PI3K and mTOR signaling in lung ﬁbroblasts.
Initial studies, aimed at deﬁning the kinetics of PI3K/mTOR and
canonical Smad signaling in pHLFs during TGF-β1-induced
collagen deposition, revealed that Smad signaling was rapid and
relatively short-lived with Smad2 phosphorylation peaking within
the ﬁrst hour and declining after 2 h (Fig. 1a). This preceded
mTORC1 signaling, as evidenced by p70S6K and 4E-BP1 phos-
phorylation (Ser65), which was observed from 2 h onwards and
was sustained for at least 12 h. Maximal PDK1-dependent
phosphorylation of Akt (Thr308) and mTORC2-dependent
phosphorylation of its substrates Akt (Ser473) and SGK1 (infer-
red by phosphorylation of the SGK1 substrate NDRG126) peaked
12 h post-stimulation.
PI3K pathway inhibition and the TGF-β1 collagen response.
We next investigated the contribution of the PI3K/mTOR sig-
naling axis to TGF-β1-induced collagen synthesis by quantitative
high-content imaging of collagen I deposition under macro-
molecular crowding conditions22,27. TGF-β1 (1 ng/ml) increased
pHLF collagen deposition by 2.1-fold (±0.1) after 72 h (Fig. 1b, c).
To determine whether canonical PI3K signaling was necessary for
this response, we investigated the effect of highly selective inhi-
bitors of critical components of the PI3K/Akt axis: PI3K (Com-
pound 2), Akt (MK2206), and PDK1 (GSK23344770)
(Supplementary Fig. 1). A schematic of inhibitors used with their
corresponding targets is shown in Fig. 2a. Compound 2, an ATP-
competitive inhibitor selective for class 1 PI3K isoforms that
exhibits low afﬁnity for mTOR (Supplementary Table 2), atte-
nuated both Akt Thr308 and Ser473 phosphorylation in addition
to inhibiting phosphorylation of downstream substrates of Akt
(PRAS40 and GSK3β; Fig. 2b). In contrast, this inhibitor had no
effect on TGF-β1-induced collagen deposition (Fig. 2c). Similarly,
treatment with either the allosteric inhibitor of Akt, MK2206, or
the PDK1 inhibitor, GSK2334479, attenuated Akt phosphoryla-
tion at both Thr308 and Ser473 sites in addition to downstream
Akt signaling (Fig. 2d, f) but had no effect on the TGF-β1-induced
collagen response (Fig. 2e, g). The mTORC2 substrates, Akt and
SGK1, require sequential phosphorylation by PDK1 and
mTORC2 to become fully activated. TGF-β1-induced mTORC2-
mediated downstream signaling (Akt and NDRG) was attenuated
in the presence of a PDK1 inhibitor, but collagen synthesis was
unaffected (Fig. 2f, g). Taken together, these data led us to
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conclude that canonical PI3K/Akt signaling is redundant for
TGF-β1-induced collagen synthesis.
The role of mTOR signaling in the TGF-β1 collagen response.
Having ruled out a role for the linear PI3K/Akt pathway, we next
investigated the contribution of mTOR signaling to TGF-β1-
induced collagen synthesis using four structurally distinct, potent
and highly selective ATP-competitive mTOR kinase inhibitors
that target both mTORC1 and mTORC2 (Supplementary Table 2,
Supplementary Fig. 1). The ﬁrst compound, AZD8055, attenuated
TGF-β1-induced phosphorylation of the mTORC1 substrates,
p70S6K (Thr389) and 4E-BP1 (Thr37/46, Ser65), as well as the
mTORC2 substrates, Akt (Ser473) and SGK1 (phosphorylated
NDRG1 Thr346) in a concentration-dependent manner (Fig. 3a).
This compound was also highly effective at inhibiting TGF-β1-
induced collagen synthesis (Fig. 3b, c). This observation was
reproducible in ﬁbroblasts derived from 4 additional donors
(Supplementary Table 3). Similar inhibitory proﬁles were
observed with the ATP-competitive mTOR inhibitors; Torin-1
(Fig. 3d and Supplementary Fig. 3a), Compound 1 (Fig. 3e and
Supplementary Fig. 3b), and CZ415 (Fig. 3f and Supplementary
Fig. 2). Supplementary Table 4 illustrates the comparative selec-
tivity proﬁles of CZ415 and AZD8055 derived from the MS-based
binding analysis. The complete selectivity proﬁles are available in
Supplementary Data 1. AZD8055 also signiﬁcantly attenuated the
peak increase in COL1A1 mRNA levels following TGF-β1 sti-
mulation suggesting that mTOR signaling acts, at least in part, by
inﬂuencing COL1A1 mRNA levels (Fig. 3g).
Having established a key role for mTOR in mediating the
ﬁbrogenic effects of TGF-β1, we next investigated the relative
contributions of mTORC1 and mTORC2 by CRISPR-Cas9 gene
editing of either RPTOR (mTORC1) or RICTOR (mTORC2).
Successful gene editing was conﬁrmed by Western blot (Fig. 3h).
TGF-β1-induced collagen synthesis was maintained in RICTOR-
edited cells (Fig. 3i, j). In contrast, RPTOR gene editing resulted in
near complete inhibition of TGF-β1-induced collagen synthesis.
These observations were conﬁrmed in a second assay based on
the quantitation of hydroxyproline in procollagen by reverse
phase HPLC (Fig. 3k) and provided strong evidence that
mTORC1 is a key signaling node involved in mediating the
potent ﬁbrogenic effects of TGF-β1.
The PI3K pathway is considered to be the primary pathway for
the activation of mTORC1 (Fig. 2a). Akt phosphorylates TSC2 at
multiple sites to relieve the inhibition on Rheb and stimulate
mTORC1 activity. However, neither PI3K nor Akt inhibition
inﬂuenced mTORC1 downstream signaling despite attenuating
TSC2 phosphorylation at the Akt-dependent Ser939 residue
(Supplementary Fig. 4a, b). MAPK signaling via ERK represents a
parallel pathway which also leads to the phosphorylation of TSC219.
Phosphorylation of TSC2 at the ERK-dependent Ser664 residue was
retained when ﬁbroblasts were stimulated with TGF-β1 in the
presence of inhibitors targeting PI3K, Akt, or PDK1 (Supplemen-
tary Fig. 4b). In order to rule out the possibility of ERK-mediated
compensation when the Akt pathway is fully inhibited, we show
that the ERK inhibitor AS-703026, used either on its own or in
combination with the Akt inhibitor (MK2206), did not attenuate
TGF-β1-induced collagen deposition (Supplementary Fig. 4c, d).
Inhibition of RSK1 (SL0101), which lies downstream of ERK and
also phosphorylates TSC2, similarly did not inhibit the TGF-β1
collagen response (Supplementary Fig. 4e). This led us to conclude
that TGF-β1-induced collagen synthesis is not dependent on Akt-
or MAPK-mediated phosphorylation of TSC2.
Canonical Smad signaling was found to precede the activation
of mTORC1 signaling in response to TGF-β1 stimulation (Fig. 1a),
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Fig. 1 TGF-β1 induces Smad phosphorylation and mTOR signaling and upregulates collagen I deposition in control primary human lung ﬁbroblasts. Control
primary human lung ﬁbroblasts (pHLFs) were stimulated with TGF-β1 (1 ng/ml) for 30min to 48 h prior to cell lysis. Phosphorylation of speciﬁed proteins is
shown by Western blot (a). Additionally, pHLFs were stimulated with increasing concentrations of TGF-β1 (1 pg/ml to 30 ng/ml) for 72 h with collagen I
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of view imaged per well) and cell counts obtained by staining nuclei with DAPI. Representative images are shown in c. Scale bars= 360 µm. Each data
point shown is mean ± SEM (n= 4) and is representative of 3 independent experiments
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but whether Smad is necessary for the activation of mTORC1 is
not known. Targeted knockdown of Smad3 in pHLFs attenuated
mTORC1-dependent phosphorylation of p70S6K and 4E-BP1,
indicating that the activation of mTORC1 is Smad3-dependent
(Fig. 4a, b). Smad3 knockdown was also associated with a
signiﬁcant reduction in TGF-β1-induced COL1A1 mRNA levels
and collagen synthesis (Fig. 4c, d). Further support for the
conclusion that Smad signaling is temporally upstream of mTOR
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was obtained by showing that AZD8055, Torin-1, and Com-
pound 1 have no effect on the phosphorylation of either Smad2 or
3 (Fig. 3a and Supplementary Fig. 3).
TGF-β1-induced collagen synthesis is rapamycin-insensitive.
Having established the importance of mTORC1 signaling for
TGF-β1-induced collagen synthesis, we examined the effect of the
partial allosteric mTORC1 inhibitor, rapamycin. In contrast to
ATP-competitive mTOR inhibitors, which directly bind to the
mTOR catalytic site, rapamycin had no effect on TGF-β1-induced
collagen synthesis (Fig. 5a) or the peak increase in COL1A1
mRNA levels (Fig. 5b). Comparison of the effect of AZD8055
versus rapamycin on downstream mTORC1 substrates revealed
that treatment with rapamycin completely inhibited p70S6K
phosphorylation, whereas its effects on mTORC1-mediated 4E-
BP1 phosphorylation were modest (Fig. 5c). In contrast,
Fig. 3a shows that the ATP-competitive mTORC1/2 inhibitor,
AZD8055, completely inhibited phosphorylation of both
mTORC1 substrates, p70S6K and 4E-BP1, notably affecting all
measured 4E-BP-1 phosphorylation sites.
To further interrogate the role of mTORC1 downstream
substrates in TGF-β1-induced collagen synthesis, we investigated
the effects of p70S6K inhibition with LY2584702. This compound
(1 μM) inhibited the phosphorylation of its downstream sub-
strate, ribosomal protein S6 (Fig. 5d), but had no effect on
a b
c d
β actin
8
COL1A1
6
R
el
at
iv
e 
ex
pr
es
si
on
4
120
100
C
ol
la
ge
n 
I s
ig
na
l
(%
 T
G
F
β 1 
co
nt
ro
l)
80
60
40
20
0
2
0
– –+ +
Control siRNA Smad3 siRNA
– –+ +
Control siRNA Smad3 siRNA
***
****
Smad 3
S
m
ad
3 
si
R
N
A
C
on
tr
ol
 s
iR
N
A
 
50
50
C
on
tr
ol
 s
iR
N
A
C
on
tr
ol
 s
iR
N
A
S
m
ad
3 
si
R
N
A
p70S6K
p-p70S6K (Thr389)
– + +
70
70
15
15
p-4E-BP1 (Ser65)
4E-BP1
TGF-β1
TGF-β1 TGF-β1
Fig. 4 mTORC1 signaling is Smad-dependent. pHLFs were transfected with control siRNA or siRNA targeting Smad3 and Smad3 protein expression
measured by Western blot (a). Following transfection, pHLFs were stimulated with TGF-β1 (1 ng/ml) for 12 h and mTORC1 signaling evaluated by Western
blot analysis (b). An irrelevant lane has been spliced out of the prepared images (a) and (b). Uncropped gels are shown in Supplementary Fig. 9. COL1A1
mRNA levels were assessed by real-time RT qPCR at 24 h (n= 3) (c). Relative expression was calculated using 2−ΔCt. ΔCt was calculated from the
geometric mean of two reference genes. Collagen I deposition was measured by macromolecular crowding assay at 72 h (d). Data are expressed as
collagen I signal normalized to cell count (n= 4 ﬁelds of view imaged per well) calculated as a percentage of the TGF-β1 -treated control (n= 5). Data are
presented as mean ± SEM and are representative of 2 independent experiments. Differences between groups were evaluated with two-way ANOVA with
Tukey multiple comparison testing, ***p < 0.001, ****p < 0.0001
Fig. 3 ATP-competitive inhibition of mTOR and mTORC1 knockout attenuates collagen I deposition in pHLFs. pHLFs were pre-incubated with vehicle (0.1%
DMSO) or increasing concentrations of AZD8055 prior to stimulation with TGF-β1 (1 ng/ml). Cells were lysed at 1 h to assess Smad phosphorylation and at
12 h to assess the phosphorylation of speciﬁed proteins, assessed by Western blot (a). pHLFs were pre-incubated with vehicle (0.1% DMSO) or increasing
concentrations of AZD8055 (b, c), Torin-1 (d), Compound 1 (e), or CZ415 (f) and stimulated with TGF-β1 for 72 h with collagen I deposition assessed by
macromolecular crowding assay. Data are expressed as collagen I signal calculated as a percentage of the TGF-β1-treated control (n= 4 ﬁelds of view
imaged per well) and cell counts obtained by staining nuclei with DAPI (n= 4). Data are representative of 5 independent experiments. Scale bars=
360 µm. IC50 values were calculated using 4-parameter non-linear regression: AZD8055, IC50= 368 nM, 95% CI 220–616 nM; Torin-1, IC50= 57.8 nM,
95% CI 38–87.7 nM; Compound 1, IC50= 2.6 µM, CI 2.1–3.1 µM; CZ415, IC50= 165.9 nM, 95% CI 135.4–203 nM. COL1A1 mRNA levels were assessed by
real-time RT qPCR after pre-incubation of pHLFs with vehicle (0.1% DMSO) or 1 µM AZD8055 prior to TGF-β1 stimulation for 24 h (n= 4) (g). Relative
expression was calculated using 2−ΔCt. ΔCt was calculated from the geometric mean of two reference genes. pHLFs were modiﬁed by CRISPR-Cas9 gene
editing using guide RNAs (gRNA) targeting exon 26 of RPTOR or exon 29 of RICTOR. Analysis of the resultant levels of Raptor and Rictor protein are shown
(h). CRISPR-Cas9-edited pHLFs were stimulated with TGF-β1 (1 ng/ml) for 72 h, with collagen I deposition normalized to cell count assessed by
macromolecular crowding assay (n= 3) (i). Representative images are shown in j. In addition, supernatants were collected from CRISPR-Cas9-edited
pHLFs treated with TGF-β1 (1 ng/ml) for 72 h and hydroxyproline was quantiﬁed using HPLC (n= 3) (k). Data are presented as means ± SEM. Differences
between groups were evaluated with two-way ANOVA with Tukey multiple comparison testing, ***p < 0.001, ****p < 0.0001
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TGF-β1-induced collagen synthesis (Fig. 5e). p70S6K is a member
of the AGC kinase superfamily that is sequentially phosphorylated
by PDK1 and mTOR to become fully activated. PDK1 inhibition
attenuated p70S6K phosphorylation by mTORC1 (Fig. 5f), but as
previously mentioned had no effect on TGF-β1-induced collagen
synthesis (Fig. 2f). Taken together, these data led us to conclude
that rapamycin-sensitive mTORC1 signaling through p70S6K is
dispensable for TGF-β1-induced collagen synthesis.
The role of 4E-BP1 downstream of mTORC1 signaling. Having
ruled out p70S6K, we next addressed the potential involvement of
4E-BP1. 4E-BP1 is a major translational repressor which inhibits
cap-dependent translation by binding to eukaryotic translation
initiation factor (eIF)4E, preventing the recruitment of eIF4G and
the subsequent formation of the translation initiation complex.
Dissociation of 4E-BP1 from eIF4E is dependent on the stepwise
phosphorylation of at least four critical sites by mTORC1
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Fig. 5 Rapamycin-insensitive mTORC1 signaling mediates TGF-β1-induced collagen I deposition. pHLFs were pre-incubated with vehicle (0.1% DMSO) or
increasing concentrations of rapamycin (a) and LY2584702 (e) and stimulated with TGF-β1 for 72 h with collagen I deposition assessed by macromolecular
crowding assay. Data are expressed as collagen I signal as a percentage of the TGF-β1-treated control (n= 4 ﬁelds of view imaged per well) and cell counts
obtained by staining nuclei with DAPI. Data are presented as mean ± SEM (n= 4) and are representative of 3 independent experiments. Additionally,
pHLFs were pre-incubated with vehicle (0.1% DMSO) or increasing concentrations of rapamycin (c), 1 µM LY2584702 (d), or 1 µM GSK2334470 (f) prior
to stimulation with TGF-β1 (1 ng/ml). Cells were lysed 12 h later and the phosphorylation of speciﬁed proteins was assessed by Western blot. COL1A1
mRNA levels were assessed by RT qPCR after pre-incubation of pHLFs with vehicle (0.1% DMSO) or 100 nM rapamycin prior to TGF-β1 stimulation for
24 h (b). Relative expression was calculated using 2−ΔCt. ΔCt was calculated from the geometric mean of two reference genes. Data are presented as
mean ± SEM (n= 4). Differences between groups were evaluated with two-way ANOVA. For immunoprecipitation of the m7GTP cap, pHLFs were pre-
incubated with vehicle (0.1% DMSO), 1 µM AZD8055 or 100 nM rapamycin prior to TGF-β1 stimulation. Protein levels were assessed by Western blot (g)
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(threonine residues 37, 46, and 70 and serine residue 65) and
allows eIF4G to bind eIF4E to facilitate cap-dependent transla-
tion28,29. Cap pull-down studies with the m7GTP cap analog with
lysates from TGF-β1-treated ﬁbroblasts in the presence of either
rapamycin or AZD8055 revealed that TGF-β1 stimulation led to
the release of 4E-BP1, allowing eIF4G to bind to the cap complex
(Fig. 5g). Treatment with AZD8055 enhanced the binding of
4E-BP1 to the cap complex, excluding eIF4G despite TGF-β1
stimulation. In contrast, rapamycin treatment failed to prevent
4E-BP1 dissociation from the cap complex in TGF-β1-stimulated
ﬁbroblasts. Taken together, these data suggest that only ATP-
competitive mTOR inhibition, which fully suppresses 4E-BP1
phosphorylation downstream of mTORC1 to enhance 4E-BP1
binding to the cap (Fig. 3a and Supplementary Fig. 3), is capable
of preventing the initiation of TGF-β1-induced cap-dependent
translation.
To further interrogate the role of 4E-BP1, we knocked down
4E-BP1 by targeted siRNA (which should mimic full 4E-BP1
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Fig. 6 mTORC1/4E-BP1 axis mediates the TGF-β1 collagen I response in pHLFs. pHLFs were transfected with control siRNA or siRNA targeting 4E-BP1. 4E-
BP1 protein expression was measured by Western blot (a). Following transfection, pHLFs were preincubated with 1 μM AZD8055 or vehicle (0.1% DMSO)
prior to stimulation with TGF-β1 (1 ng/ml) for 72 h. Collagen I deposition was assessed by macromolecular crowding assay (n= 4) (b). COL1A1 mRNA
levels at 24 h were assessed by real-time RT qPCR (n= 3) (g). pHLFs expressing a 4E-BP1-4A dominant-negative phosphomutant were treated with
doxycycline (1 μg/ml) or media control for 24 h prior to TGF-β1 stimulation. Immunoprecipitation of the m7GTP cap was performed and protein levels
assessed by Western blot (c). Collagen deposition was measured at 72 h by macromolecular crowding assay (n= 12) (d). Representative images are
shown in e. Scale bars= 360 µm. COL1A1 mRNA levels were measured at 24 h (n= 6) (f). Data are presented as means ± SEM. For real-time RT-PCR,
relative expression was calculated using 2−ΔCt. ΔCt was calculated from the geometric mean of two reference genes. For collagen deposition assays all
data are expressed as collagen I signal (n= 4 ﬁelds of view imaged per well) normalized to cell count. All data are representative of at least 3 independent
experiments. Differences between groups were evaluated with two-way ANOVA with Tukey multiple comparison testing, *p < 0.05, ***p < 0.001, ****p <
0.0001. Proposed model is shown in h (schematic generated by author J.D.E.). TGF-β1 activates the Smad3 pathway which in turn directly inﬂuences early
increases in COL1A1 mRNA levels (1), as has been previously described. Smad3 activation subsequently activates the mTORC1/4E-BP1 axis (2). This
cascade regulates maximal COL1A1 mRNA levels through an unknown mechanism, likely involving the translational regulation of a protein intermediate (3)
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phosphorylation). This led to an enhanced TGF-β1 response and
interfered with the ability of AZD8055 to inhibit TGF-β1 induced
collagen synthesis (Fig. 6a, b) indicating that the inhibitory effects
of AZD8055 are mediated by blocking the phosphorylation of 4E-
BP1. To further interrogate the mTORC1/4E-BP1 axis, we
generated pHLFs expressing a doxycycline-inducible 4E-BP1
dominant negative phospho-mutant (with mTORC1 phosphor-
ylation sites Thr37, Thr46, Ser65, and Thr70 replaced by alanine,
abbreviated as 4E-BP1-4A29). We reasoned that the expression of
4E-BP1-4A would mimic the effects of ATP-competitive mTOR
inhibition on collagen deposition. m7GTP cap pull-down
conﬁrmed doxycycline treatment induced 4E-BP1-4A expression
and constitutive binding of 4E-BP1-4A to eIF4E (Fig. 6c).
Doxycycline had no effect on 4E-BP1 expression or collagen
deposition in untransduced pHLFs (Supplementary Fig. 5a, b).
Expression of the dominant negative 4E-BP1-4A phosphomutant
resulted in a marked attenuation of TGF-β1-induced collagen
deposition to below constitutive baseline values (Fig. 6d, e).
4E-BP1-4A expression also inhibited TGF-β1-induced COL1A1
mRNA levels (Fig. 6f); whereas 4E-BP1 siRNA knockdown
similarly rescued the inhibitory effect of AZD8055 on TGF-β1-
induced COL1A1 mRNA levels (Fig. 6g), indicating that the
mTORC1/4E-BP1 axis acts at least in part, at the level of
regulating COL1A1 mRNA levels to mediate the ﬁbrogenic effects
of TGF-β1 in pHLFs. Our proposed model is shown in Fig. 6h.
mTORC1 signaling and ﬁbrogenesis in IPF. All studies thus far
were performed with pHLFs from control donors. Since IPF
ﬁbroblasts have been reported to be epigenetically modiﬁed
(reviewed in ref. 8), we next examined the role of mTOR signaling
in IPF-derived ﬁbroblasts. ATP-competitive mTOR inhibition
with AZD8055 (Fig. 7a) and CZ415 (Fig. 7b) was also found to
inhibit TGF-β1-induced collagen synthesis in a concentration-
dependent manner in IPF ﬁbroblasts. This observation was
conﬁrmed in 4 additional IPF donor lines (Supplementary
Table 3). As observed for control ﬁbroblasts, the TGF-β1 collagen
response was completely rapamycin-insensitive in IPF ﬁbroblasts
(Fig. 7c).
We were also successful in performing CRISPR-Cas9 gene
editing of RPTOR (mTORC1) or RICTOR (mTORC2) in IPF
ﬁbroblasts as evidenced by marked reduction in Raptor and
Rictor protein expression (Fig. 7d). As observed for control
ﬁbroblasts, TGF-β1-induced collagen deposition was maintained
in RICTOR-silenced cells but RPTOR gene editing resulted in
near-complete inhibition of TGF-β1-induced collagen synthesis
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Fig. 7mTORC1 plays a critical role in mediating the pro-ﬁbrotic effects of TGF-β1 in IPF-derived lung ﬁbroblasts. IPF human lung ﬁbroblasts (IPF-HLFs) were
pre-incubated with vehicle (0.1% DMSO) or increasing concentrations of AZD8055 (a), CZ415 (b), or rapamycin (c) and stimulated with TGF-β1 (1 ng/ml)
for 72 h with collagen I deposition assessed by macromolecular crowding assay. Data are expressed as collagen I signal calculated as a percentage of the
TGF-β1-treated control (n= 4 ﬁelds of view imaged per well) and cell counts obtained by staining nuclei with DAPI. Each data point shown is mean ± SEM
(n= 4) and is representative of 5 independent experiments. IC50 values were calculated using 4-parameter non-linear regression: AZD8055, IC50=
604 nM, 95% CI 415 nM to 1 µM; CZ415, IC50= 245.3 nM, 95% CI 136.7–541 nM. Additionally, IPF-HLFs were modiﬁed by CRISPR-Cas9 gene editing
using gRNAs targeting exon 26 of RPTOR or exon 29 of RICTOR. Analysis of the resultant levels of Raptor and Rictor protein are shown (d). CRISPR-Cas9-
edited IPF-HLFs were also stimulated with TGF-β1 (1 ng/ml) for 72 h, with collagen I deposition assessed by macromolecular crowding assay (e). Scale
bars= 360 µm
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(Fig. 7e) indicating that mTORC1 is also a key signaling node
during ﬁbrogenesis in IPF ﬁbroblasts.
We next explored the potential role of mTOR in the broader
context of regulating the TGF-β1-modulated matrisome by
conducting a proteomic analysis of IPF ﬁbroblasts grown under
identical macromolecular crowding conditions in the presence
of either CZ415 or rapamycin (Fig. 8a). We focus here on the
core matrisome proteins (http://matrisomeproject.mit.edu/
other-resources/human-matrisome/) and proteins involved in
collagen synthesis and degradation (https://reactome.org/
PathwayBrowser/#/R-HSA-1650814); the complete data is in
Supplementary Data 2. Among these matrisome proteins, about
50% (169/330) were detectable in our cell system. Figure 8a
represents a heatmap of the 50 proteins that showed a fold change
(FC) (pAdj < 0.05 and |FC| > 1.2 in both replicates) in any one
condition relative to the negative TGF-β1 control. Among these,
41 proteins showed increased levels and 9 showed decreased
levels after 24 h stimulation with TGF-β1. To identify differences
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Fig. 8 ATP-competitive mTOR inhibition attenuates TGF-β1-induced matrisome protein expression in vitro and collagen synthesis in IPF lung slices. IPF
human lung ﬁbroblasts (IPF-HLFs) were pre-incubated with vehicle (0.1% DMSO), rapamycin (100 nM) or the mTOR inhibitor CZ415 (5 µM) prior to
stimulation with TGF-β1 (1 ng/ml) for 24 h. Proteomic analysis representing fold change (FC) of core matrisome proteins and proteins involved in collagen
synthesis and degradation in lysates of TGF-β1+ vehicle/drug-treated ﬁbroblasts versus negative TGF-β1 control is displayed in a heatmap. Only proteins
with up- or down-regulation (pAdj < 0.05 and |FC| > 1.2 for both replicates) in any treatment versus negative TGF-β1 control are represented (50 proteins)
(a). Quantitative proﬁles across treatments are displayed as line charts (b). Human IPF lung tissue slices generated from IPF lung transplant tissue were
treated with vehicle (0.1% DMSO) or increasing concentrations of CZ415 for 120 h. Levels of P1NP in supernatants from 4 slices per condition were
assessed by ELISA (c). Data are representative of 5 independent donors. Differences between conditions were evaluated with one-way ANOVA with
Dunnett’s multiple comparison testing, **p < 0.005. Human IPF lung tissue slices (n= 4) from 2 donors were treated with vehicle (0.1% DMSO) or CZ415
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between CZ415 and rapamycin on the TGF-β1 response, we
selected proteins that were upregulated by TGF-β1, inhibited by
CZ415, and insensitive to rapamycin treatment as depicted in
Fig. 8b. This group included several collagen types (I, III, V, VII),
as well as other ECM proteins (e.g., elastin/ELN) and matricel-
lular proteins (e.g., SPARC) and the key procollagen processing
enzyme, ADAMTS2 (also known as procollagen I N-proteinase).
Of note, the procollagen processing enzyme BMP1 (responsible
for cleaving the C-propeptide of ﬁbrillar collagens) presented the
same proﬁle but just missed the signiﬁcance cut-off for one
replicate (pAdj= 0.051). Finally, the proteoglycan Agrin (AGRN)
was not affected by TGF-β1 or rapamycin, but was signiﬁcantly
down-regulated by CZ415 relative to both TGF-β1 treatment and
vehicle control levels.
In order to determine if there is a functional link between
mTOR signaling and collagen synthesis in the context of human
ﬁbrotic lung disease, we next evaluated the effect of the most
potent and selective ATP-competitive mTOR inhibitor, CZ415, in
live unmanipulated precision-cut lung slices generated from IPF
lung transplant tissue. De novo collagen synthesis was monitored
by measuring the release of the human procollagen 1 formation
marker; amino-terminal peptide (P1NP) by proprietary ELISA
(Nordic Bioscience). Figure 8c shows that P1NP levels in slice
supernatants were reduced in the presence of CZ415 in a
concentration-dependent manner. This observation was con-
ﬁrmed in tissue slices obtained from 5 additional IPF donors
(Supplementary Table 5). To conﬁrm target engagement of the
mTORC1/4E-BP1 axis, 4E-BP1 phosphorylation was measured in
tissue slice homogenates following exposure to CZ415 (1 μM).
Inhibition of supernatant P1NP levels was associated with
signiﬁcant attenuation of 4E-BP1 Ser65 and Thr37/46 phosphor-
ylation (Fig. 8d).
mTORC1/4E-BP1 is a core ﬁbrogenic pathway. We also
examined the relative contribution of mTORC1 and
mTORC2 signaling in primary human dermal ﬁbroblasts
(pHDFs), hepatic stellate cells (HSCs), and cancer-associated
ﬁbroblasts (CAFs) derived from patients with lung adenocarci-
noma by CRISPR-Cas9 gene editing to disrupt mTORC1
(RPTOR) and mTORC2 (RICTOR) signaling. These studies
revealed that the magnitude of the TGF-β1 collagen response was
variable and appeared to be related to higher baseline levels of
collagen I deposition observed, especially for HSCs. Moreover,
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Fig. 9 mTORC1/4E-BP1 axis mediates collagen I deposition in other mesenchymal cells. Lung adenocarcinoma-associated ﬁbroblasts (CAFs), primary
human dermal ﬁbroblasts (pHDFs), and primary hepatic stellate cells (HSCs) were modiﬁed by CRISPR-Cas9 gene editing using gRNAs targeting exon 26
of RPTOR or exon 29 of RICTOR. Analysis of the resultant levels of Raptor and Rictor protein are shown (a, e, i). CRISPR-Cas9-edited CAFs, pHDFs, and
HSCs were stimulated with TGF-β1 (1 ng/ml) for 72 h, with collagen I deposition assessed by macromolecular crowding assay (b, f, j). Data are expressed
as collagen intensity (n= 4 ﬁelds of view imaged per well) normalized to cell count. Data are presented as mean ± SEM (CAFs n= 5, pHDFs n= 6, HSCs
n= 8). CAFs, pHDFs, and HSCs were transfected with control siRNA or siRNA targeting 4E-BP and 4E-BP1 protein expression was measured (c, g, k).
Following transfection, cells were preincubated with 1 μM (CAFs) or 300 nM (pHDFs, HSCs) AZD8055 or vehicle prior to stimulation with TGF-β1 for 72 h.
Collagen I deposition was analyzed by macromolecular crowding assay (d, h, l). Data are expressed as collagen intensity (n= 4 ﬁelds of view imaged per
well) normalized to cell count. Data are presented as mean ± SEM (CAFs n= 3, pHDFs n= 4, HSCs n= 5). Differences between groups were evaluated
with two-way ANOVA with Tukey multiple comparison testing, *p < 0.05, ***p < 0.001, ****p < 0.0001
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CAFs displayed evidence of heterogeneous phenotypes as has
been extensively reported30. For the purpose of this study, we
focused on collagen-producing CAFs. Successful gene editing was
conﬁrmed at the protein level for all lines tested (Fig. 9a, e, i).
Importantly, all cell types in which RPTOR was disrupted were
unable to mount a full TGF-β1 induced collagen response. In
contrast, this response was fully maintained in cells in which
RICTOR was disrupted (Fig. 9b, f, j). We also determined whether
4E-BP1 siRNA was able to restore the attenuated TGF-β1 induced
collagen response in cells treated with AZD8055. 4E-BP1 was
successfully knocked down at the protein level by targeted siRNA
(Fig. 9c, g, k). In all cell types examined, 4E-BP1 siRNA rescued
the impact of AZD8055 on TGF-β1 induced collagen synthesis
(Fig. 9d, h, l), suggesting that the mTORC1/4E-BP1 axis repre-
sents a common ﬁbrogenic signaling hub across stromal cells
derived from different organs.
Discussion
Highly synthetic myoﬁbroblasts are the key effector cells involved
in excessive ECM deposition in multiple ﬁbrotic conditions,
including IPF. We recently reported that combined pan-PI3K and
mTOR inhibition with Omipalisib attenuates TGF-β1-induced
collagen synthesis in human lung ﬁbroblasts (HLFs)22. We now
dissect the relative contributions of PI3K and mTOR signaling to
TGF-β1-induced collagen deposition and report that rapamycin-
insensitive mTORC1/4E-BP1 signaling is critical for this response
in control and IPF-derived ﬁbroblasts, whereas upstream cano-
nical PI3K/Akt signaling is dispensable. Moreover, the effects of
mTOR inhibition extend to other matrisome proteins implicated
in the ﬁbrotic response. Targeting mTOR by ATP-competitive
mTOR inhibition further blocks collagen synthesis in live IPF
tissue slices. Finally, the mTORC1/4E-BP1 axis is also critical for
collagen I synthesis by dermal ﬁbroblasts, HSCs, and lung cancer-
associated ﬁbroblasts.
PI3K/Akt signaling in response to TGF-β1 stimulation in HLFs
has previously been implicated in pro-survival and anti-apoptotic
signaling31,32. We now provide strong pharmacological evidence
that this axis is however not required for TGF-β1-induced col-
lagen synthesis in that class 1 PI3K, Akt, and PDK1 inhibitors,
which robustly attenuated Akt signaling, consistently had no
effect on TGF-β1-induced collagen deposition in our assays.
Although this observation contrasts with previous studies
reporting a role for PI3K in TGF-β1 mediated collagen synth-
esis33–35, these earlier studies employed ﬁrst generation PI3K
inhibitors, LY294002 and wortmannin, which inhibit a broad
range of other PI3K-related proteins, including mTOR36. In
contrast, Compound 2 used here exhibits exquisite selectivity for
all class 1 PI3K isoforms over mTOR.
Whilst the PI3K/Akt axis is one of the best-characterized
pathways leading to mTORC1 activation37, PI3K and Akt inhi-
bition did not impact TGF-β1-induced mTORC1 downstream
signaling. This is consistent with the temporal kinetics of the
signaling response to TGF-β1, in that maximal phosphorylation
of mTORC1 substrates was consistently observed at least 10 h
before maximal phosphorylation of Akt. We considered the
potential involvement of a number of potential PI3K/Akt inde-
pendent pathways that could regulate mTORC1 activation in
response to TGF-β1 stimulation. The TSC complex is a key
control switch for mTORC1 activation and is phosphorylated by
multiple other inputs besides Akt, including MAPK, Wingless-
related integration (Wnt) signaling, redox and nutrient status19.
Our data show that, while MAPK-dependent TSC2 phosphor-
ylation occurs in response to TGF-β1, pharmacological inhibition
of the major MAPKs implicated in TSC phosphorylation, ERK or
RSK1, did not inhibit the downstream TGF-β1 collagen response.
Furthermore, we ruled out the possibility of compensation
between the Akt and ERK pathways, as reported in other cell
contexts38, on the basis of a lack of an inhibitory effect observed
by combined inhibition of Akt and ERK.
In contrast to the lack of evidence supporting the involvement
of PI3K and Akt and MAPK signaling, ATP-competitive mTOR
inhibition had a profound inhibitory effect on TGF-β1-induced
collagen synthesis (with the most potent and selective compounds
tested displaying an IC50 within the nanomolar range) in control
and IPF ﬁbroblasts. We subsequently established a critical role for
rapamycin-insensitive mTORC1 signaling in mediating the
ﬁbrogenic responses of TGF-β1 on the basis of evidence obtained
by CRISPR-Cas9 gene-editing of RPTOR and the lack of effect of
rapamycin treatment on this response, as has been reported by
others39,40.
Compared to ATP-competitive mTOR inhibitors, which
directly bind to the mTOR catalytic site, rapamycin is an allos-
teric inhibitor that exclusively binds to the FKBP12/rapamycin-
binding (FRB) domain of mTORC1 to restrict the access of
substrates to the catalytic site. Previous phosphoproteomic stu-
dies have shown that the mTORC1 substrates, p70S6K and 4E-
BP1, are differentially sensitive to rapamycin treatment, based on
the avidity with which they are phosphorylated by mTORC1.
p70S6K (Thr389) and 4E-BP1 (Ser65) are weakly phosphorylated
by mTORC1 and readily sensitive to rapamycin treatment,
whereas 4E-BP1 (Thr37/46) are avidly phosphorylated and
insensitive to rapamycin treatment41. In contrast, all p70S6K and
4E-BP1 sites are sensitive to ATP-competitive mTOR inhibi-
tors41. Several observations led us to exclude a role for mTORC1/
p70S6K in mediating the TGF-β1 collagen response. First, TGF-
β1-induced p70S6K phosphorylation was highly sensitive to
rapamycin treatment, but rapamycin had no effect on either
TGF-β1-induced COL1A1 mRNA levels or collagen deposition.
Second, the p70S6K speciﬁc inhibitor, LY2584702, did not inhibit
the TGF-β1 collagen response. Finally, treatment with the PDK1
inhibitor (GSK2334470) prevented TGF-β1-induced p70S6K
phosphorylation, but again had no effect on TGF-β1-induced
collagen synthesis.
Our data provides strong support that mTORC1 mediates the
ﬁbrogenic effects of TGF-β1 via a 4E-BP1-dependent mechanism.
Analysis of cap-dependent translation complex formation in
response to TGF-β1 stimulation suggests that attenuation of 4E-
BP1 (Ser65) phosphorylation alone by rapamycin is not sufﬁcient
to block mTORC1-mediated cap-dependent translation and fur-
ther that the potent effect of ATP-competitive mTOR inhibition
on TGF-β1-induced collagen synthesis is likely mediated via a
marked inhibitory effect on the phosphorylation of multiple 4E-
BP1 sites. Conclusive evidence for the critical involvement of 4E-
BP1 was provided by data demonstrating that inducible expres-
sion of a dominant-negative 4E-BP1 phosphomutant led to avid
4E-BP1 binding to the 5′ cap and a profound inhibitory effect on
the TGF-β1-induced collagen response. In addition, silencing 4E-
BP1 by siRNA targeted knockdown (which effectively mimics 4E-
BP1 phosphorylation), rescued the inhibitory effect of the mTOR
inhibitor, AZD8055, on TGF-β1-induced collagen synthesis,
indicating that AZD8055 exerts its anti-ﬁbrotic effects via a 4E-
BP1-dependent mechanism. These ﬁndings are consistent with a
recent report suggesting the involvement of mTORC1/4E-BP1 in
basal collagen synthesis in the context of bronchiolitis obliter-
ans40. However, we should caution that our ﬁndings highlighting
a critical role for mTORC1/4E-BP1 conﬂict with a previous study
reporting a role for mTORC2 based on Western blotting for
collagen following shRNA knockdown of RICTOR39. We are
currently unable to explain these contrasting ﬁndings, but it is
worth commenting that we employed the most selective phar-
macological tools available to probe multiple kinases along the
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PI3K/Akt/mTOR axis in combination with a highly efﬁcient
CRISPR-Cas9 gene-editing approach and used two com-
plementary methods for assessing collagen synthesis (macro-
molecular crowding assays and hydroxyproline levels). Further
studies using conditional tissue-speciﬁc RPTOR and RICTOR
deﬁcient mice may help resolve the issue with respect to the
relative contributions of mTORC1 versus mTORC2 signaling and
ﬁbrogenesis in an in vivo setting.
In terms of identifying the mechanism by which mTORC1/4E-
BP1 inﬂuences the TGF-β1 collagen response, several lines of
investigation suggest that this occurs, at least in part, at the level
of regulating COL1A1 mRNA levels. First, AZD8055 attenuated
TGF-β1-induced COL1A1 mRNA levels; second, the impact of
AZD8055 on COL1A1 mRNA levels could be rescued by targeted
4E-BP1 silencing; and third, inducible expression of a dominant-
negative 4E-BP1 phosphomutant blocked the increase in TGF-β1-
induced COL1A1 mRNA levels. Given the key role of the cano-
nical Smad pathway in mediating downstream TGF-β1 signaling,
we also examined how mTORC1 signaling might intercept with
the Smad pathway to regulate TGF-β1-induced collagen expres-
sion. We focused our functional interrogations on Smad3, which
has been strongly implicated in mediating the ﬁbrogenic effects of
TGF-β1 in vitro and in vivo42,43. Our data show that Smad3 and
mTORC1 signaling are both critical and cooperate to promote
TGF-β1-induced collagen deposition. We now propose a potential
model whereby canonical Smad3 signaling inﬂuences immediate-
early COL1A1 gene transcription as previously described42, but is
also critical for the activation of the mTORC1/4E-BP1 axis fol-
lowing TGF-β1 stimulation. This axis in turn is critical for TGF-
β1-induced collagen expression, at least in part, by inﬂuencing
peak COL1A1 mRNA levels, possibly by inﬂuencing the transla-
tion of an as yet unidentiﬁed protein intermediate (Fig. 6h).
Seminal ribosome proﬁling studies by the Sabatini laboratory
have demonstrated that mRNAs with a terminal oligopyrimidine
(TOP) motif in the 5′UTR (which includes ribosomal proteins
and translation elongation factors) exhibit enhanced sensitivity to
translational regulation by the mTORC1/4E-BP1 axis29. Sequence
analysis of the 5′UTR of COL1A1 and COL1A2 mRNAs (RefSeq
accession NM_000088, NM_000089, dbTSS) revealed that these
transcripts do not satisfy the original criteria for TOP/TOP-like
motifs. However, given the profound inhibitory effect observed by
disrupting mTORC1/4E-BP1 signaling on TGF-β1-induced col-
lagen synthesis, we propose that mTORC1/4E-BP1 might act at
multiple levels of the collagen biosynthetic cascade. Further
extensive studies, including ribosome proﬁling, will be required to
pinpoint the precise mechanism by which mTORC1/4E-BP1
inﬂuences TGF-β1-induced collagen expression.
A number of ATP-competitive mTOR inhibitors are now
reaching the clinical phase of development in other disease
contexts (including equally fatal conditions such as cancer44), we
therefore extended our analysis to determine the impact of ATP-
competitive mTOR inhibition on other TGF-β1 regulated matri-
some proteins in IPF-derived ﬁbroblasts by comparing the effect
of CZ415 (the most potent and selective ATP-competitive mTOR
inhibitor tested, Supplementary Fig. 2) with rapamycin. Our
proteomic studies revealed that there were major differences
between the anti-ﬁbrotic potential of these two compounds: in
addition to inhibiting collagen I, CZ415 inhibited other major
components of the ﬁbrogenic niche including several other col-
lagen types (III, V, VII), elastin (ELN), several matricellular
proteins, and collagen processing enzymes. In contrast, the
upregulation of these proteins was completely rapamycin-
insensitive. Of the CZ415-sensitive proteins, only ELN was clas-
siﬁable as a TOP mRNA whereas COL5A1, MFAP2, and MFAP4
are classiﬁable as potentially TOP-like. The translation of these
mRNAs may therefore be directly regulated by the mTORC1/4E-
BP1 axis, further supporting the notion that ATP-competitive
mTOR inhibition acts at multiple steps to modulate the TGF-β1
ECM response. We further propose that the lack of a direct anti-
ﬁbrogenic effect by rapamycin might, in part, explain the recent
negative IPF clinical trial of the closely related rapalog,
everolimus45.
Having established a basis for exploring ATP-competitive
mTOR inhibition as a potential novel anti-ﬁbrotic strategy, we
focused on establishing a human-disease-based rationale for
targeting this axis in the context of IPF. Support for this strategy
in the most commonly used animal model of bleomycin-induced
lung injury and ﬁbrosis in mice became available during the
course of this study based on the ATP-competitive mTOR inhi-
bitor, MLN012839. The bleomycin model is widely regarded to be
helpful in terms of enabling mechanistic investigations relevant to
ﬁbrogenesis in an in vivo context. However, it also has well-
recognized limitations in terms of recapitulating important fea-
tures of the human disease and downstream clinical predict-
ability46. We therefore elected to further investigate the potential
of ATP-competitive mTOR inhibition in IPF by investigating the
impact of such an approach on collagen synthesis in live
precision-cut ex-vivo lung slices derived from transplant tissue
from IPF patients. These studies revealed that the potent and
selective ATP-competitive mTOR inhibitor, CZ415, was highly
effective at inhibiting collagen synthesis in these IPF slices. Our
data further provided evidence of target pathway engagement, as
the anti-ﬁbrotic effect of CZ415 was associated with inhibition of
4E-BP1 phosphorylation at residues demonstrated throughout
our study to be critical for regulation of the collagen biosynthetic
cascade. Future studies with clinically developable ATP-
competitive mTOR inhibitors focused on determining their
safety, efﬁcacy, and therapeutic window in animal models of
pulmonary ﬁbrosis will be needed in order to further support the
translatability of this approach for the treatment of IPF.
Excessive ECM deposition leading to architectural distortion
and functional organ impairment is the hallmark of all ﬁbrotic
diseases47 and is also a feature of the stromal reaction in cancer1.
Most of the work presented herein focused on the collagen
response in the context of IPF, the most rapidly progressive and
fatal of all ﬁbrotic diseases. However, it is recognized that
although the initial insult may be distinct in terms of promoting
the development of ﬁbrosis across different organs, there are
likely to be common pro-ﬁbrotic pathways that drive ECM
deposition in different disease contexts2. Data obtained using
CRISPR-Cas9 gene editing of RPTOR and RICTOR in combina-
tion with data obtained by 4E-BP1 siRNA rescue of the inhibitory
effects of AZD8055 on the TGF-β1 collagen response provide
strong support that our key observation regarding the critical role
of the mTORC1/4E-BP1 signaling during ﬁbrogenesis is gen-
eralizable to other key effector cells of the ﬁbrotic response in the
context of the skin (pHDFs), the liver (HSCs), and the stromal
reaction in lung adenocarcinoma (CAFs).
In conclusion, we report evidence based on multiple lines of
investigation that the mTORC1/4E-BP1 axis plays a critical role
in mediating the ﬁbrogenic effects of TGF-β1, the most potent
pro-ﬁbrotic mediator characterized to date. We propose that
targeting this axis may hold broad promise as a potential anti-
ﬁbrotic strategy in the context of multiple ﬁbrotic conditions and
the stromal reaction in cancer.
Methods
Primary cell culture. pHLFs were grown from explant cultures of IPF or non-IPF
control lung tissue. Brieﬂy, lung parenchyma was cut into 1 mm3 fragments and
placed on 10 cm tissue culture dishes with Dulbecco’s modiﬁed Eagle’s medium
(DMEM) (ThermoFisher Scientiﬁc) supplemented with 10% (v/v) fetal calf
serum (FCS) (Sigma-Aldrich), penicillin (100 U/ml), streptomycin (100 μg/ml),
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and 2.5 μg/ml amphotericin B (ThermoFisher Scientiﬁc). Fibroblasts developed
into a near conﬂuent monolayer of cells after 3–4 weeks. Experiments were con-
ducted on cells between passages 2 and 8. CAF cell cultures were established
through the Tracking Cancer Evolution through Therapy (TRACERx) clinical
study (REC reference 13/LO/1546). CAFs were grown from explant culture of
tumor tissue from patients with lung adenocarcinoma. Primary normal human
adult dermal ﬁbroblasts and human HSCs were purchased from Lonza (#CC-2511)
and Zen-Bio (#HP-F-S), respectively.
To generate a HLF cell line expressing a dominant-negative mutant of 4E-BP1,
ﬁbroblasts were transduced with lentiviral tet-on plasmid. pCW57.1-4EBP1_4xAla
was a gift from David Sabatini (Addgene plasmid #38240)29. Cells were selected
with 2 μg/ml puromycin (Sigma-Aldrich) for 5 days. Expression of the 4E-BP1
mutant was induced with 1 μg/ml doxycycline treatment (Sigma-Aldrich) for 24 h.
For experiments analyzed by Western blot or real-time RT-PCR, cells were
seeded into 6-well plates (Nunc™, ThermoFisher Scientiﬁc) and cultured for 48 h
prior to serum starvation. Fibroblast cultures assessed for collagen I deposition
were seeded into black-walled 96-well plates (Corning) for 24 h prior to low-serum
(0.4%) starvation. All cell lines tested negative for mycoplasma.
Immunoblotting. Fibroblasts were lysed in ice-cold PhosphoSafe® buffer (Merck
Millipore) supplemented with protease inhibitors (cOmpleteMini™, Roche). Fol-
lowing SDS PAGE, gel to membrane transfer and blocking, protein phosphoryla-
tion was assessed by Western blot using commercially available antibodies
(catalogue numbers and dilutions supplied in Supplementary Table 1), and
visualization of membranes was performed using ImageQuant TL v8.1 software
(GE Healthcare). Following stripping, membranes were blocked and re-probed for
total levels of speciﬁed proteins. Uncropped Western blots for all ﬁgures are shown
in Supplementary Figs. 6–15.
Determination of type I collagen deposition. Type I collagen biosynthesis and
deposition was determined in a 96-well format by a high-content immuno-
ﬂuorescence-based macromolecular crowding assay modiﬁed from a previously
described method27. Brieﬂy, ﬁbroblasts were cultured in DMEM (0.4% FCS) in the
presence of ascorbic acid and a dissolved mix of Ficoll 70 and Ficoll 400 as
macromolecular crowding agents. For compound studies, ﬁbroblasts were incu-
bated either with vehicle (DMSO) or a speciﬁed inhibitor (Supplementary Table 2,
Supplementary Fig. 1) for 1 h prior to stimulation with TGF-β1 (1 ng/ml) and
further incubation for 72 h at which point cell monolayers were ﬁxed for immu-
noﬂuorescence. Fibroblasts were stained with a collagen I antibody (Sigma-
Aldrich) and AlexaFluor488 secondary antibody (ThermoFisher Scientiﬁc), nuclei
were counterstained with DAPI. Images of ﬁbroblasts and collagen deposition were
captured and the ﬂuorescent signal quantiﬁed on the ImageXpress Micro XLS
high-content imaging system at 20× magniﬁcation (Molecular Devices).
COL1A1 real-time quantitative PCR. Total RNA was extracted from adherent cells
using RNeasy Mini kit (Qiagen) according to the manufacturer’s instructions. Real-
time PCR was performed using a Mastercycler Realplex ep gradient S (Eppendorf).
Primer sequences: COL1A1 forward 5′ ATGTAGGCCACGCTGTTCTT 3′ and
COL1A1 reverse 5′ GAGAGCATGACCGATGGATT 3′. PCR ampliﬁcation was
carried out for 40 cycles at a melting temperature of 95 °C for 15 s and an annealing
temperature of 60 °C for 1 min. A dissociation curve was analyzed for each PCR
experiment to assess primer–dimer formation or contamination. Relative mRNA
level quantiﬁcations of target genes were determined using the cycle threshold
method with ATP5B and β2 microglobulin (β2M) as housekeeping genes (Pri-
merDesign Ltd. Primer sequences for housekeeping genes are proprietary, acces-
sion numbers supplied by manufacturer: NM_001686 (ATP5B), NM_004048
(β2M)), and the data were expressed as the expression relative to the housekeeping
genes.
CRISPR-Cas9 gene editing. Guide RNA (gRNA) sequences were designed using
the Deskgen design platform (https://www.deskgen.com/guidebook/advanced.
html). Primary cells were electroporated with a CRISPR ribonucleoprotein (RNP)
complex targeting either RICTOR exon 29 or RPTOR exon 26 using the Lonza 4D
Nucleofector™ system (Basel, Switzerland). MiSeq analysis was performed to gen-
otype the loci that were targeted by the CRISPR RNP complex and showed 94%
allele mutation frequency. Loss of Rictor and Raptor protein expression was
conﬁrmed using Western blotting. The gRNA sequences and primers used are
given in Table 1.
siRNA transfection. Conﬂuent cells were serum starved and transfected with
10–50 nM ON-TARGETplus siRNA pools targeting EIF4EBP1 or SMAD3 (Dhar-
macon) or Silencer Select negative control siRNA (ThermoFisher Scientiﬁc) using
RNAiMax lipofectamine (Invitrogen) according to the manufacturer’s instructions.
m7GTP immunoprecipitation. Fibroblasts were lysed in ice-cold Pierce immu-
noprecipitation lysis buffer (ThermoFisher Scientiﬁc) supplemented with EDTA-
free protease and phosphatase inhibitors (ThermoFisher Scientiﬁc). Association of
proteins with the 5′ mRNA cap was determined by ﬁrst incubating lysates with
m7GTP-bound sepharose beads (Jena Bioscience), followed by Western blot to
assess the association of relevant proteins.
Matrisome proteomics. IPF-derived lung ﬁbroblasts were grown in macro-
molecular crowding conditions and treated with either vehicle (DMSO), rapamycin
(100 nM), or the mTOR inhibitor CZ415 (5 µM). Following compound treatment
for 3 h, TGF-β1 (1 ng/ml) was added for 24 h, and cells were harvested by scraping
of the culture surface. PBS-washed cell pellets were then processed for LC-MS/MS
analysis (please see Supplementary materials and methods for a detailed protocol).
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange consortium via the PRIDE partner repository48 with dataset identiﬁer
PXD010164.
Collagen synthesis in precision-cut lung slices. To generate precision-cut lung
slices, IPF tissue was ﬁrst inﬂated with 3% agarose dissolved in RPMI and cooled.
8 mm diameter cores were generated and 250 µm slices were produced using the
Krumdieck tissue slicer (Alabama Research and Development). Slices were cultured
for 24 h in DMEM (10% CO2/100% humidity) prior to incubation with the mTOR
inhibitor, CZ415, for 120 h (media changed and CZ415 re-added at 72 h). The
effect of CZ415 on levels of the collagen formation marker, P1NP, in tissue
supernatant was assessed by proprietary competitive ELISA (Nordic Bioscience)49.
Tissue slices were homogenized and analyzed for the phosphorylation of 4E-BP1
by MSD immunoassay (Meso Scale Discovery, USA).
Quantiﬁcation of hydroxyproline from cellular supernatants. Fibroblast pro-
collagen production was assessed by high-performance liquid chromatography
(HPLC) quantitation of hydroxyproline in supernatants from conﬂuent ﬁbroblast
monolayers. Brieﬂy, proteins were precipitated by the addition of ethanol to a ﬁnal
concentration of 67% (vol/vol) at 4 °C overnight and separated from free amino
acids with 0.45 μm ﬁlters (Millipore). Filters with adherent proteins were hydro-
lyzed in hydrochloric acid (6M) at 110 °C overnight. Hydrolysates were decolor-
ized with charcoal, ﬁltered through a 0.65 μm ﬁlter (Millipore) (Sigma Aldrich) and
then derivatized with 7-chloro-4-nitrobenzo-2-oxa-1,3-diazole (Acros Organics,
ThermoFisher Scientiﬁc) prior to reverse-phase HPLC (Agilent 1100 series, Agilent
Technologies) for the isolation of hydroxyproline with an acetonitrile gradient
using a LiChrosopher, 100 RP-18 column.
Statistical analysis. Concentration–response curves, mRNA and tissue slice data
ﬁgures were constructed using GraphPad Prism version 7.00. Four-parameter non-
linear regression analyses were used to generate IC50 values from
concentration–response curves. Additionally, where speciﬁed in relevant ﬁgure
legends, data were analyzed by Student’s t-test, one-way ANOVA with Dunnett’s
multiple-comparisons testing or two-way ANOVA with Tukey multiple-
comparisons testing. Data were considered statistically signiﬁcant at p < 0.05.
Study approval. Samples of IPF lung tissue were obtained from patients under-
going lung transplant or surgical lung biopsy following informed signed consent
Table 1 Guide RNAs and primer sequences used for CRISPR-Cas9 gene editing
RICTOR, exon 29
gRNA AATATCGGCTCATCAAATTGGGG
MiSeq forward primer ACACTCTTTCCCTACACGACGctcttccgatctATGACCTACCCTCTGATGGAAAG
MiSeq reverse primer TGACTGGAGTTCAGACGTGTGctcttccgatctTTTTTCTCTCTCAGAGATGAGGT
RAPTR, exon 26
gRNA CCGCGTCTACGACACAGAAGGATGG
MiSeq forward primer ACACTCTTTCCCTACACGACGctcttccgatctACCCAACCAAATGGCAGTGACAC
MiSeq reverse primer TGACTGGAGTTCAGACGTGTctcttccgatctTGCCTGTGTTTGGCTCTAGGACA
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and with research ethics committee approval (11/NE/0291—NRES Committee
North East—Newcastle and North Tyneside 1, 10/H0504/9—National Institute of
Health Biomedical Research Unit Advanced Disease Biobank, Royal Brompton
Hospital, 10/H0720/12—London—Hampstead Research Ethics Committee and 12/
EM/0058—NRES Committee East Midlands—Nottingham 2). Cancer-associated
ﬁbroblast (CAF) cell cultures were established within the Tracking Cancer Evo-
lution through Therapy (TRACERx) clinical study (13/LO/1546—NRES London—
Camden and Islington). Tissue for lung slice experiments was obtained from
Asterand Europe (Royston, UK) in compliance with the UK Human Tissue Act
2004. The human biological samples were sourced ethically and their research use
was in accord with the terms of the informed consents.
Data availability
The mass spectrometry proteomics data have been deposited to the Proteo-
meXchange consortium via the PRIDE repository, and are publicly available with
the dataset identiﬁer PXD010164. Complete selectivity proﬁles of CZ415 and
AZD8055 are available in Supplementary Data 1. Complete matrisome and
collagen-modifying protein data is available in Supplementary Data 2. All
remaining data will be available from the corresponding author upon reasonable
request.
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